In addition, similar to CD-47 combination therapy, applying CD40 receptor agonists after inhibiting the CSF-1 receptor can remarkably enhance T-cell activity, thereby boosting anti-tumor immune responses [106]. This evidence concerns the gene CSF1R and neoplasm.